Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997530 | 0.89 | GPR119 (0.56) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL31586104 | 0.87 | GPR119 (0.52) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL25726262 | 0.87 | GPR119 (0.54) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL18586154 | 0.87 | GPR119 (0.54) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL2195346 | 0.85 | GPR119 (0.53) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL25413411 | 0.85 | NR1H2 (0.44) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL21998106 | 0.85 | GPR119 (0.50) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL904142 | 0.84 | GPR119 (0.57) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL6749163 | 0.84 | GPR119 (0.52) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 | |
| SCHEMBL26351092 | 0.84 | GPR119 (0.52) | GPR119NAMPTUSP2SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GPR119 1443/4885NAMPT 3507/4885USP2 740/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | GPR119 3223/4885NAMPT 3269/4885USP2 270/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | GPR119 932/4885NAMPT 2728/4885USP2 684/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR119 2426/4885NAMPT 1694/4885USP2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.